Datapoint: Centene Completes PANTHERx Sale
July
20
Centene Corp. last week completed its sale of specialty pharmacy arm PANTHERx to Vistria Group, General Atlantic and Nautic Partners. Centene originally purchased the rare drug company in December 2020. The insurer said in a July 14 press release that it intends to use the windfall to “repurchase stock and the balance to reduce debt.” Centene is also in the process of selling Magellan Rx to Prime Therapeutics, with the two deals valued at $2.8 billion. Centene is currently the fourth-largest insurer in the U.S., with 20,988,628 members.
Source: AIS’s Directory of Health Plans
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile